These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27497028)

  • 1. Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: A meta-analysis of the contributions of specific plants.
    Chen M; May BH; Zhou IW; Sze DM; Xue CC; Zhang AL
    Crit Rev Oncol Hematol; 2016 Sep; 105():18-34. PubMed ID: 27497028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Medicine for Relief of Nausea and Vomiting in the Treatment of Colorectal Cancer Using Oxaliplatin-Based Chemotherapy: A Systematic Review and Meta-Analysis.
    Chen MH; May BH; Zhou IW; Zhang AL; Xue CC
    Phytother Res; 2016 May; 30(5):741-53. PubMed ID: 26912094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response.
    Chen M; May BH; Zhou IW; Xue CC; Zhang AL
    Integr Cancer Ther; 2016 Mar; 15(1):40-59. PubMed ID: 26254190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review.
    Chen M; May BH; Zhou IW; Xue CC; Zhang AL
    Phytother Res; 2014 Jul; 28(7):976-91. PubMed ID: 24343974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
    Garziera M; Virdone S; De Mattia E; Scarabel L; Cecchin E; Polesel J; D'Andrea M; Pella N; Buonadonna A; Favaretto A; Toffoli G
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
    Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tolerability of Oxaliplatin-Based Adjuvant Chemotherapy for Patients with Colorectal Cancer].
    Matsuo H; Nakanishi M; Arita T; Murayama Y; Kuriu Y; Kosuga T; Konishi H; Morimura R; Komatsu S; Shiozaki A; Ikoma H; Ichikawa D; Fujiwara H; Okamoto K; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2112-4. PubMed ID: 26805281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
    Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
    Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
    Ge L; Wang YF; Tian JH; Mao L; Zhang J; Zhang JH; Shen XP; Yang KH
    J Clin Pharm Ther; 2016 Aug; 41(4):383-91. PubMed ID: 27338003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
    Liu R; Huang M; Zhao X; Peng W; Sun S; Cao J; Ji D; Wang C; Guo W; Li J; Yin J; Zhu X
    Oncotarget; 2015 Nov; 6(36):39018-27. PubMed ID: 26528696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
    Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
    Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
    Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
    Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
    Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of oxaliplatin in the treatment of colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):15-20. PubMed ID: 11204657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.